Small molecules anti-HIV therapeutics targeting CXCR4

Current Pharmaceutical Design

Volumn 14, Issue 4, 2008, Pages 385-404

  Grande, Fedora ^a   Garofalo, Antonio ^b   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Chemokine receptors; CXCR4 antagonists; HIV infection

Indexed keywords

4,4' [CARBONYLBIS[IMINO 1H PYRROLE 4,2 DIYLCARBONYLIMINO(1 METHYL 1H PYRROLE 4,2 DIYL)CARBONYLIMINO]]BIS(1,7 NAPHTHALENESULFONIC ACID); 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ALIPHATIC AMINE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMPELOPSIN; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; BICYCLAM DERIVATIVE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPENTAPEPTIDE; CYCLOTETRAPEPTIDE; DIPICOLYLAMINE ZINC COMPLEX; DISTAMYCIN A DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; KRH 1636; MARAVIROC; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PHENYLALANINE DERIVATIVE; PIPERAZINEDIONE; PLERIXAFOR; POLYPHEMUSINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1; T 140; TETRAHYDROQUINOLINE DERIVATIVE; THIAZOLYLISOTHIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CXCR4 PROTEIN, HUMAN;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METASTASIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; METABOLISM; METHODOLOGY;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HUMANS; RECEPTORS, CXCR4;

EID: 42049122872     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783497714     Document Type: Review

References (174)

1. UNAIDS. Report on the global AIDS epidemic 2006 www.unaids.org, 2006.
2. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr Pharm Des 2004; 10: 2041-62.
3. Louie M, Markowitz M. Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. Antivir Res 2002; 55: 15-25.
4. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354: 729-33.
5. Nielsen MH, Pedersen FS, Kjems J. Molecular strategies to inhibit HIV-1 replication. Retrovirology 2005; 2: 10.
6. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 391: 667-73.
7. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
8. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-7.
9. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-5.
10. Bridger GJ, Skerlj R, Kaller A, Harwig C, Bogucki D, Wilson TR, et al. Chemokine receptor binding heterocyclic compounds. WO2002022599, 2002.
11. Leonard JT, Roy K. The HIV entry inhibitors revisited. Curr Med Chem 2006; 13: 911-34.
12. Cervia JS, Smith MA. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis 2003; 37: 1102-6.
13. Bourgeois R, Mercier J, Paquette-Brooks I, Cohen EA. Association between disruption of CD4 receptor dimerization and increased human immunodeficiency virus type 1 entry. Retrovirology 2006; 3: 31.
14. Tian S, Choi WT, Liu D, Pesavento J, Wang Y, An J, et al. Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1 alpha on CXCR4 transmembrane helical domains. J Virol 2005; 79: 12667-73.
15. Meanwell NA, Kadow JF. Inhibitors of the entry of HIV into host cells. Curr Opin Drug Disc 2003; 6: 451-61.
16. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002; 7: 235-46.
17. Schols D. HIV co-receptors as targets for antiviral therapy. Curr Top Med Chem 2004; 4: 883-93.
18. Zhou N, Luo Z, Luo J, Fan X, Cayabyab M, Hiraoka M, et al. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J Biol Chem 2002; 277: 17476-85.
19. Princen K, Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth F R 2005; 16: 659-77.
20. Doms RW. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 2000; 276, 229-37.
21. Lo TM, Willem P. HIV-1 subtype C, CCR5-using viruses are detected in CD4T cells and macrophages in South African AIDS patients. Analisys by fluorescent in situ hybridization and V3 loop sequencing. Poster presentation Retrovirology 2005; 2 (Suppl 1): P58.
22. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acaa Sci USA 1997; 94: 1925-30.
23. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21: 265-304.
24. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829-33.
25. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382: 833-5.
26. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3 100, a CXCR4 antagonist with a different structure. J Virol 1999; 73: 1719-23.
27. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004; 17: 7-16.
28. Meanwell NA, Kadow JF, Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs 2007; 8: 669-81.
29. Schols D. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antivir Res 2006; 71: 216-26.
30. Palani A, Shapiro S, Clader JW, Greenlee WJ, Blythin D, Cox K, et al. Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist. Bioorg Med Chem Lett 2003; 13: 705-8.
31. Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl) carbonyl]-4-[4-[2-niethoxy-1(R)-4-(trifluoromethyl) phenyl] ethyl-3(S)-methyl-1-piperaz inyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004; 47: 2405-8.
32. Kazmierski WM, Aquino CJ, Bifulco N, Boros EE, Chauder BA, Chong PY, et al. Piperidine derivatives as CCR5 antagonists. WO2004054974, 2004.
33. Duan M, Kazmierski WM, Aquino CJ. Cyclohexyl compounds as CCR5 antagonists. WO2004054581, 2004.
34. Peckham JP, Aquino CJ, Kazmierski WM. Cyclopropyl compounds as CCR5 antagonists. WO2004055010, 2004.
35. Youngman M, Kazmierski WM, Yang H, Aquino CJ. Indane compounds as CCR5 antagonists. WO2004055012, 2004.
36. Yang H, Kazmierski WM, Aquino CJ. Pyrrolidine and azetidine compounds as CCR5 antagonists. WO2004055016, 2004.
37. Aquino CJ, Chong PY, Duan M, Kazmierski WM. Heterocyclic compounds as CCR5 antagonists. WO2004055011, 2004.
38. Delcroix-Genete D, Quan PL, Roger MG, Hazan U, Nisole, S, Rousseau C. Antiviral properties of two trimeric recombinant gp41 proteins. Retrovirology 2006; 3: 16.
39. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996; 70: 6288-95.
40. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276: 276-9.
41. Juarez J, Bendall L, Bradstock K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Design 2004; 10: 1245-59.
42. Valenzuela-Fernandez A, Palanche T, Amara A, Magerus A, Altmeyer R, Delaunay T, et al. Optimal inhibition of X4 HIV isolates by the CXC chemokine stromal cell-derived factor 1 alpha requires interaction with cell surface heparan sulfate proteoglycans. J Biol Chem 2001; 276: 26550-8.
43. Kazmierski WM, Kenakin TP, Gudmundsson KS. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem Biol Drug Des 2006; 67: 13-26.
44. Bajetto A, Bonavia R, Barbero S, Florio T, Costa A, Schettini G. Expression of chemokine receptors in the rat brain. Ann NY Acad Sci 1999; 876: 201-9.
45. Choi WT, Tian S, Deng CZ, Kumar S, Liu D, Madani N, et al. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors. J Virol 2005; 79: 15398-404.
46. Verani A, Lusso P. Chemokines as natural HIV antagonists, Curr Mol Med 2002; 2: 691-702.
47. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. Embo J 1997; 16: 6996-7007.
48. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3: 338-40.
49. Garred P, Eugen-Olsen J, Iversen AK, Benfield TL, Svejgaard A, Hofmann B. Dual effect of CCR5 delta 32 gene deletion in HIV-1-infected patients. Copenhagen AIDS Study Group. Lancet 1997; 349: 1884.
50. Maas JJ, Gange SJ, Schuitemaker H. Coutinho RA, van Leeuwen R, Margolick JB. Strong association between failure of T cell hemeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 2000; 14: 1155-61.
51. Luengo J, Shaw A. CXCR-4 receptor antagonists - thrombopoietin mimetics. WO2000066112, 2000.
52. Bachman M, Tissot A, Jegelehner A, Saudan P, Zou Y, Schmitz N, et al. Virus-like particle antigen conjugates as vaccines against AIDS, gastrointestinal cancers, coronary heart diseases or inflammatory diseases. WO2006139304, 2006.
53. Yen CF, Hu CK, Chu MC, King CHR. Preparation of aminopyrimidines as chemokine CXCR4 receptor ligands. WO2006160860, 2006.
54. Wu CH, Zhu JL, Tseng CT, Yeng CF, Shia KS, Xiang Y, et al. Preparation of benzimidazole polyamine compounds. US2006160860, 2006.
55. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 2000; 165: 3423-9.
56. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger GJ, Henson GW, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001; 167: 4686-92.
57. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001; 61: 4961-5.
58. Shim H, Liang, Z, Umbreit J, Taichman R, Goodmann M. CXCR4 antagonists and methods of their use. WO2004087068, 2004.
59. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-8.
60. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
61. Andrian UHV, Mazo I, Gauguet JM. Methods for the treatment of multiple myelome. W02006116185, 2006.
62. Shim H, Liotta D, Snyder JP, Zhan W, Liang Z. CXCR4 antagonists for the treatment of HIV infections. WO2006074426, 2006.
63. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, et al. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Tr 2006; 97: 275-83.
64. Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D, Rubin JB. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 2007; 67: 651-8.
65. Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S. Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res 2007; 13: 1562-70.
66. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003; 100: 13513-8.
67. Spoo AC, Lubbert M, Wierda WG, Burger JA, CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786-91.
68. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6: 459-69.
69. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425: 307-11.
70. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, et al. Stromal cell-derived factor-1 alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-ftmetion induces expression of a ligand and its receptor. Cancer Res 2005; 65: 6178-88.
71. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med 2007; 58:445-59.
72. Fujii N, Nakashima R, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Inv Drug 2003; 12: 185-95.
73. Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Tar 2005; 9: 1267-82.
74. Moore JP, Stevenson M. New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Bio 2000; 1: 40-9.
75. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186: 1383-8.
76. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, et al. AMD3 100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4: 72-7.
77. Zumbrunn J, Demarco JS, Lociuro S, Vrijbloed JW, Gombert F, Mukherjee R, et al. Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity. WO2004096839, 2004.
78. Sumner-Smith M, Zheng Y, Zhang YP, Twist EM, Climie SC. Antiherpetic activities of N-alpha-acetyl-nona-D-arginine amide acetate. Drug Exp Clin Res 1995; 21: 1-6.
79. Deranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997; 186: 1395-400.
80. Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, imegrin activation, and adhesion to stromal cells. Oncogene 2003; 22: 8093-101.
81. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003; 550: 79-83.
82. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005; 24: 4462-71.
83. Tamamura H, Fujisawa M, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, et al. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett 2004; 569: 99-104.
84. Daelemans D, Schols D, Witvrouw M, Pannecouque C, Hatse S, van Dooren S, et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CYC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 2000; 57: 116-24.
85. Lapidot T, Rubinstein M, Spiegel A, Fridkin M, Kalinkovich A, Shivtiel S. Inhibition of CXCR4 and/or cell motility. WO2007074456, 2007
86. Citterio P, Rusconi S. Novel inhibitors of the early steps of the HIV-1 life cycle. Expert Opin Inv Drug 2007; 16: 11-23.
87. Tamamura H, Omagari A, Oishi S, Kanamoto T, Yamamoto N, Peiper SC, et al. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg Med Chem Lett 2000; 10: 2633-7.
88. Tamamura H, Fujii N. Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists. Curr Drug Targets 2004; 4: 103-10.
89. Fujii N, Oishi S, Hiramatsu K, Araki T, Ueda S, Tamamura H, et al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew Chem Int Edit 2003; 42: 3251-3.
90. Tamamura H, Hiramatsu K, Miyimoto K, Omagari A, Oishi S, Nakashima H, et al. Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII-turn moiety. Bioorg Med Chem Lett 2002; 12: 923-8.
91. Tamamura H, Koh Y, Ueda S, Sasaki Y, Yamasaki T, Aoki M, et al. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains. J Med Chem 2003; 46:1764-8.
92. Tamamura H, Hiramatsu K, Ueda S, Wang Z, Kusano S, Terakubo S, et al. Stereoselective synthesis of [L-Arg-L /D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J Med Chem 2005; 48: 380-91.
93. Tamamura H, Otaka A, Fujii N. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides. Curr HIV Res 2005; 3: 289-301.
94. Tamamura H, Araki T, Ueda S, Wang Z, Oishi S, Esaka A, et al. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem 2005; 48: 3280-9.
95. Tamamura H, Tsutsumi H, Masuno H, Fujii N. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid, arthritis. Curr Med Chem 2007; 14: 93-102.
96. Ueda S, Oishi S, Wang ZX, Araki T, Tamamura H, Chizeau J, et al. Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J Med Chem 2007; 50: 192-8.
97. Niida A, Tanigaki H, Inokuchi E, Sasaki Y, Oishi S, Ohno H, et al. Stereoselective synthesis of 3,6-disubstituted-3,6-dihydropyridin-2-ones as potential diketopiperazine mimetics using organocopper-mediated anti-SN2' reactions and their use in the preparation of low-molecule CXCR4 antagonists. J Org Chem 2006; 71: 3942-51.
98. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/ CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004; 78: 8654-62.
99. Borthwick AD, Davies DE, Exall AM, Livermore DG, Sollis SL, Nerozzi F, et al. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. J Med Chem 2005; 48: 6956-69.
100. Wipf P, Xiao J. Convergent approach to (E)-alkene and cyclopropane peptide isosteres. Org Lett 2005; 7: 103-6.
101. Niida A, Oishi S, Sasaki Y, Mizumoto M, Tamamura H, Fujii N, et al. Facile access to (Z-alkene-containing diketopiperazine mimetics utilizing organocopper-mediated anti-S(N)2 reactions. Tetrahedron Lett 2005; 46: 4183-6.
102. Donkor IO, Sanders ML. Synthesis of a reported calpain inhibitor isolated from Streptomyces griseus. Bioorg Med Chem Lett 2001; 11: 2647-9.
103. Jenkins CL, Vasbinder MM, Miller SJ, Raines RT. Peptide bond isosteres: ester or (E)-alkene in the backbone of the collagen triple helix. Org Lett 2005; 7: 2619-22.
104. Joan HC, De Vreese K, Pauwels R, De Clercq E, Henson GW, Bridger GJ. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J Med Chem 1995; 38: 3865-73.
105. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Ch 1994; 38: 668-74.
106. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, et al. Potent and selective inhibition of human immumodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 1992; 89: 5286-90.
107. De Clercq E, Schols D. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. Antivir Chem Chemother 2001; 1: 19-31.
108. Princen K, Hatse S, Vermeire K, De Clercq E, Schols D. Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric-imaging plate reader (FLIPR) and flow cytometry. Cytom Part A 2003; 51: 35-45.
109. Hatse S, Princen K, Gerlach LO, Bridger GJ, Henson G, De Clercq E, et al. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol 2001; 60: 164-73.
110. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, et al. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 1998; 72: 6381-8.
111. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001; 276: 14153-60.
112. Liang X, Parkinson JA, Weishaupl M, Gould RO, Paisey SJ, Park HS, et al. Structure and dynamics of metallomacrocycles: recognition of zinc xylyl-bicyclam by an HIV coreceptor. J Am Chem Soc 2002; 124: 9105-12.
113. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Ch 2000; 44: 1667-73.
114. Lack NA, Green B, Dale DC, Calandra GB, Lee H, MacFarland RT, et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3 100. Clin Pharmacol Ther 2005; 77: 427-36.
115. Davies S, Serrauell N, Bolos J, Bayes M. Plerixafor hydrochloride Chemokine CXCR4 (SDF-1) antagonist stem cell-mobilizing agent. Drug Future 2007; 32: 123-136.
116. Valks GC, McRobbie G, Lewis EA, Hubin TJ, Hunter TM, Sadler PJ, et al. Configurationally restricted bismacrocyclic CXCR4 receptor antagonists. J Med Chem 2006; 49: 6162-5.
117. Bridget GJ, Boehringer EM, Wang Z, Schols D, Skerlj RT, Bogucki DE. Antiviral macrocyclic compounds. WO2000002870, 2000.
118. Hatse S, Princen K, De Clercq E, Rosenkilde MM, Schwartz TW, Hernandez-Abad PE, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol 2005; 70: 752-61.
119. Bridger GJ, Boehringer EM, Wang Z, Schols D, Skerlj R, Bogucki D. Chemokine receptor binding heterocyclic compounds. WO2001044229 A1, 2001.
120. Bridget GJ, Skerlj R, Kaller A, Harwig C, Bogucki D, Wilson TR, et al. Chemokine recpetor binding heterocyclic compounds. WO2000056729, 2000.
121. Scozzafava A, Mastrolorenzo A, Supuran CT. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem 2002; 17: 69-76.
122. Schwarz M, Wells TN, Proudfoot AE. Chemokine receptors - the next therapeutic target for HIV? Receptor Channel 2001; 7: 417-28.
123. Schols D, Claes S, Hatse S, Princen K, Vermeire K, De Clercq E, et al. Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist Curr Opin HIV AIDS 2006, 1: 361-6.
124. Bridget GJ, Skerlj R, Kaller A, Harwig C, Bogucki D, Wilson TR, et al. Chemokine receptor binding heterocyclic compounds. USPT20040171638, 2004.
125. Bridget GJ, Skerlj R, Kaller A, Harwig C, Bogucki D, Wilson TR, et al. Chemokine receptor binding heterocyclic compounds with enhanced efficacy. WO2003055876, 2003.
126. Bridget GJ, Skerlj R, Kaller A, Harwig C, Bogucki D, Wilson TR, et al. Chemokine receptor binding heterocyclic compounds. WO2002034745, 2002.
127. Crawford JB, Zhu Y, Chen G, Baird IR, Skerlj RT, Chemokine-binding heterocyclic compound salts, and methods of use thereof. USPT20060069122, 2006.
128. Crawford JB, Chen G, Gauthier D, Skerlj R, Baird IR, Wilson TR. Process for the synthesis of CXCR4 antagonist. USPT20050209277, 2005.
129. Gudmundsson K, Boggs SD. Preparation of imidazo[1,2-a]pyridine derivatives as chemokine receptor ligands with anti-HIV activity. WO2006026703, 2006.
130. Gudmundsson K, Miller JF, Turner EM. Preparation of 8- (imidazol-2-ylmethylamino)-5,6,7,8-tetrahydroquinolines that bind to chemokine receptors for use against HIV and other disorders. WO2006020415, 2006.
131. Gudmundsson K, Sebahar PR, Richardson LDA. Preparation of (quinolinylaminoalkyl)-benzimidazole derivatives as chemokine receptor ligands with anti-HIV activity. WO2006023400, 2006.
132. Gudmundsson K, Catalano JG, Svolto A. Preparation of heteroarylmethyl substituted octahydro-1, 10-phenanthrolines and analogs for treating diseases modulated by a chemokine receptor (CXCR4). W02006096444, 2006.
133. Gudmundsson K, Boggs SD. Aminotetrahydroquinolines as cytoprotectants from HIV infection, their preparation, pharmaceutical compositions, and use in therapy. W02006036816, 2006.
134. Gudmundsson K. Preparation of N-(imidazo[1,2-a]pyridin-2yl) methyl-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-amines that bind to chemokine receptors for use against HIV and other disorders. W02006076131, 2006.
135. Gudmundsson K Pyranopyridines and oxepinopyridines as protectants from HIV infection, their preparation, pharmaceutical compositions, and use in therapy. W02007008539, 2007.
136. Makino T. Heterocyclic compounds having NOS inhibitory activities. WO199923069, 1999.
137. Oplinger JA, Shearer BG, Bigham EC, Furfine ES, Garvey EP. Substituted urea and isothiourea derivatives as NO synthase inhibitors. WO19951009619, 1995.
138. Glickman F, Streiff M, Thoma G, Zerwes H. Isothiourea derivatives. WO2005085219 2005.
139. Decaudin D. Peripheral benzodiazepine receptor and its clinical targeting. Anti-Cancer Drug 2004; 15: 737-45.
140. Deng J, Dayam R, Neamati N. Patented small molecule inhibitors of p53-MDM2 interaction. Expert Opin Ther Pat 2006; 16: 165-188.
141. Kamal A, Ramesh G, Laxman N, Ramulu P, Srinivas O, Neelima K, et al. Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity. J Med Chem 2002; 45: 4679-88.
142. Kamal A, Rao MV, Laxman N, Ramesh G, Reddy GS. Recent developments in the design, synthesis and structure-activity relationship studies of pyrrolo[2,1-c][1,4]benzodiazepines as DNA-interactive antitumour antibiotics. Curr Med Chem 2002; 2: 215-54.
143. Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, et al. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem 2001; 44: 737-48.
144. Raboisson P, Marugan JJ, Schubert C, Koblish HK, Lu T, Zhao S, et al. Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. Bioorg Med Chem Lett 2005; 15: 1857-61.
145. Pyrrolo[2,1-c],[1,4]benzodiazepine and indole conjugates evaluated as anticancer agents, Cancer Weekly, 2006.
146. Breslin HJ, Kukla MJ, Kromis T, Cullis H, De Knaep F, Pauwels R, et al. Synthesis and anti-HIV activity of l,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. Truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on es (TIBO) analogues. Bioorgan Med Chem 1999; 7: 2427-36,
147. Marshall G. Substituted benzodiazepines as inhibitors of the chemokine receptor CXCR4 USPT20050192272, 2005.
148. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV- 1 activity. P Natl Acad Sci. USA 2003; 100: 4185-90.
149. Yamazaki T, Saitou A, Ono M, Yokoyama S, Bannai K, Hirose K, et al. Novel nitrogenous compound and usa thereof. WO2003029218, 2003.
150. Murakami T, Yoshida A, Tanaka R, Mitsuhashi S, Hirose K, Yanaka M, et al. Topics in HIV Medicine® Highlights of the 11th Conference on Retroviruses and Opportunistic Infection San Francisco, CA, 2004, 541.
151. Yamazaki T, Kikumoto S, Ono M, Saitou A, Takahashi J, Kumamura S, et al. Amine compounds and use thereof. WO2004024697, 2004.
152. kokubo M, Ochiai H, Takaoka Y, Shibayama S. Preparation of diazacycloalkane-containing N,N-bis(imidazol-2-ylmethyl)amine- sand related N,N-bis(heteroarylmethyl)amines as antagonists of chemokine receptor CXCR4. WO 2007058322, 2007.
153. Kokubo M, Tanaka M, Ochiai H, Takaoka Y, Shibayama S. Preparation of heterocyclic compounds containing basic group as CXCR4 antagonists. WO 2007049771, 2007.
154. Ojida A, Mito-Oka Y, Inoue MA, Hamachi I. First artificial receptors and chemosensors toward phosphorylated peptide in aqueous solution. J Am Chem Soc 2002; 124: 6256-8.
155. Tamamura H, Ojida A, Ogawa T, Tsutsumi H, Masuno H, Nakashima H, et al. Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. J Med Chem 2006; 49: 3412-5.
156. Fujii N, Hamachi I, Ojida A, Tamamura H, Nakashima H. Novel CXCR4 antagonists and use thereof. WO 2007074871, 2007.
157. Zeng S, Luo GQ, Liu DY. The chemotaxis effect of ampelopsin on the immunocytes. Zhong Yao Cai 2006; 29: 260-2.
158. Luo GQ, Zeng S, Liu DY. Inbibitory effects of ampelopsin on angiogenesis. Zhong Yao Cai 2006; 29: 146-50.
159. Liu D, Zheng HQ, Luo GQ. Effects of ampelopsin on invasion and metastasis of B 16 mouse melanoma in vivo and in vitro. Zhongguo Zhong Yao Za Zhi 2003; 28: 957-61.
160. Liu DY, Ye JT, Yang WH, Yan J, Zeng CH, Zeng S. Ampelopsin, a small molecule inhibitor of HIV-1 infection targeting HIV entry. Biomed Environ Sci 2004; 17: 153-64.
161. Howard OM, Korte T, Tarasova NI, Grimm M, Turpin JA, Rice WG, et al. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukocyte Biol 1998; 64: 6-13.
162. Clanton DJ, Buckheit RW Jr, Terpening SJ, Kiser R, Mongelli N, Borgia AL, et al. Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antivir Res 1995; 27: 335-54.
163. Howard OM, Oppenheim JJ, Hollingshead MG, Covey JM, Bigelow J, McCormack JJ, et al. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. J Med Chem 1998; 41: 2184-93.
164. Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, He HX, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77: 13376-88.
165. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switchhitter. AIDS Res Hum Retrov 2005; 21: 171-89.
166. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, Massip P, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acq Imm Def Synd 2005; 38: 382-92.
167. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 2005; 13: 269-77.
168. Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J. Molecular switch for alternative confermations of the HIV- I V3 regioa: im- plications for phenotype conversion. Proc Natl Acad Sci USA 2006; 103: 13950-5.
169. Lehmann C, Daumer M, Boussaad I, Sing T, Beerenwinkel N, Lengauer T, et al. J Clin Virol 2006; 37: 3004.
170. Westhy M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, et al. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Virol 2006; 80: 4909-20.
171. Mild M, Esbjomsson J, Fenyo EM, Medstrand P. Frequent intrapatient recombination between human immunodeficiency virus type 1 RS and X4 envelopes: implications for coreceptor switch. J Virol 2007; 81: 3369-76.
172. Agrawal L, Lu X, Jin Q, Alkhatib G. Anti-HIV therapy: Current and future directions. Curr Pharm Des 2006; 12(16): 2031-55.
173. Markovic I. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement. Curr Pharm Des 2006; 12(9): 1105-19.
174. Pohlmann S, Reeves JD. Cellular entry of HIV: Evaluation of therapeutic